DK3302527T3 - Manipuleret CCL20-låst-dimerpolypeptid - Google Patents

Manipuleret CCL20-låst-dimerpolypeptid Download PDF

Info

Publication number
DK3302527T3
DK3302527T3 DK16804201.8T DK16804201T DK3302527T3 DK 3302527 T3 DK3302527 T3 DK 3302527T3 DK 16804201 T DK16804201 T DK 16804201T DK 3302527 T3 DK3302527 T3 DK 3302527T3
Authority
DK
Denmark
Prior art keywords
ccl20
manipulated
dimer polypeptide
locked dimer
locked
Prior art date
Application number
DK16804201.8T
Other languages
English (en)
Inventor
Brian F Volkman
Anthony E Getschman
Sam T Hwang
Yasutomo Imai
Francis C Peterson
Original Assignee
Medical College Wisconsin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College Wisconsin Inc filed Critical Medical College Wisconsin Inc
Application granted granted Critical
Publication of DK3302527T3 publication Critical patent/DK3302527T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK16804201.8T 2015-06-03 2016-05-31 Manipuleret CCL20-låst-dimerpolypeptid DK3302527T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170347P 2015-06-03 2015-06-03
PCT/US2016/034956 WO2016196429A1 (en) 2015-06-03 2016-05-31 An engineered ccl20 locked dimer polypeptide

Publications (1)

Publication Number Publication Date
DK3302527T3 true DK3302527T3 (da) 2020-03-30

Family

ID=57441846

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16804201.8T DK3302527T3 (da) 2015-06-03 2016-05-31 Manipuleret CCL20-låst-dimerpolypeptid

Country Status (8)

Country Link
US (1) US10738095B2 (da)
EP (2) EP3666282A1 (da)
JP (1) JP6786526B2 (da)
AU (1) AU2016271292B2 (da)
CA (1) CA2988086C (da)
DK (1) DK3302527T3 (da)
ES (1) ES2776243T3 (da)
WO (1) WO2016196429A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US20030215421A1 (en) 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
WO2001017558A2 (en) 1999-09-08 2001-03-15 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
US20040197329A1 (en) 2000-10-13 2004-10-07 Yasunori Nakayama Remedies or preventives for rheumatoid arthritis
WO2002062850A2 (en) 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
MXPA04002575A (es) 2001-09-20 2004-06-18 Schering Corp Quimiocinas como adyuventes de respuesta inmune.
US20030140361A1 (en) 2001-09-24 2003-07-24 Brennan Thomas J. CCR6 chemokine receptor disruptions, compositions and methods relating thereto
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US20060275295A1 (en) 2001-12-18 2006-12-07 Denis Jullien Activity of THAP-family chemokine-binding domains
US20060240016A1 (en) 2001-12-18 2006-10-26 Luc Aguilar Activity of THAP-family chemokine-binding domains
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2004024075A2 (en) 2002-09-11 2004-03-25 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CA2572334A1 (en) 2004-07-01 2006-01-19 New York University Compositions and methods for modulation of ror.gamma.t
US7399831B2 (en) 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
EP1814911A2 (en) 2004-11-04 2007-08-08 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
ATE437889T1 (de) 2005-12-02 2009-08-15 Apceth Gmbh & Co Kg Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
BRPI0720647A2 (pt) 2006-12-29 2014-01-14 Osprey Pharmaceuticals Usa Inc Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
US7923016B2 (en) * 2008-02-27 2011-04-12 Medical College Of Wisconsin Engineered CXCL12 α locked dimer polypeptide
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
SG10201610247QA (en) 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
EP2393492A1 (en) 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
NZ611269A (en) 2010-11-19 2015-03-27 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012142501A1 (en) 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use

Also Published As

Publication number Publication date
JP2018517707A (ja) 2018-07-05
US20180237486A1 (en) 2018-08-23
AU2016271292A1 (en) 2017-12-21
WO2016196429A1 (en) 2016-12-08
JP6786526B2 (ja) 2020-11-18
EP3302527A4 (en) 2018-12-12
EP3302527B1 (en) 2020-01-08
EP3302527A1 (en) 2018-04-11
CA2988086C (en) 2023-09-19
US10738095B2 (en) 2020-08-11
EP3666282A1 (en) 2020-06-17
AU2016271292B2 (en) 2022-04-14
CA2988086A1 (en) 2016-12-08
ES2776243T3 (es) 2020-07-29

Similar Documents

Publication Publication Date Title
DK3197453T3 (da) Kimært protein
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK4089113T3 (da) Polypeptider
DK3305788T3 (da) Janus-kinase-hæmmer
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3331528T3 (da) Muskarinagonister
DK3360890T3 (da) Genterapi
DK3753929T3 (da) Dimere kontrastmidler
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3270930T3 (da) Præeklampsi
DK3702450T3 (da) Protein
DK3259358T3 (da) Forøget proteinekspression
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3274482T3 (da) Stenborsknop
DK3099793T3 (da) Protein
DK3318308T3 (da) Badmintonketsjer
DE112015005906A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
KR20180085014A (ko) 펩티드 조성물
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage